Skip to main content
Equibles

Balyasny Asset Management L.P.

Position in EDIT — Editas Medicine, Inc.

CIK 1218710 Chicago, IL
Back to EDIT Full portfolio

Position in EDIT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$121,947
-$1,529,820 QoQ
Shares Held
37,638
-97.1% QoQ
Ownership
0.025%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#93
of 216 holders
Holding Since
Jun 2021
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in EDIT Over Time

Shares Held

Position Value (USD)

Derivatives in EDIT

reported options exposure · as of Sep 30, 2022
CallValue
$306,000
CallShares
25,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Balyasny Asset Management L.P. holds $2,351,657,469 across 178 Biotechnology names. EDIT ranks #167 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 APGE
Apogee Therapeutics, Inc.
 1,665,102 $221,008,988
2 INSM
INSMED Inc
 1,326,430 $141,423,966
3 BBIO
BridgeBio Pharma, Inc.
 1,230,052 $91,614,272
4 ABVX
Abivax S.A.
 603,840 $80,467,718
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 145,005 $72,028,333
6 TNGX
Tango Therapeutics, Inc.
 2,016,379 $63,032,007
7 CYTK
Cytokinetics Inc
 711,676 $60,627,678
8 BMRN
Biomarin Pharmaceutical Inc
 1,054,613 $60,344,955

All Filings in EDIT

Export CSV
11 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $121,947 37,638
2024-12-31 $1,651,767 1,300,604
2024-09-30 $593,459 174,035
2024-06-30 $177,305 37,967
2024-03-31 $2,171,908 292,710
2023-12-31 $600,941 59,323
2022-12-31 $3,068,486 345,940
2022-09-30 $306,000 25,000
2022-09-30 $1,042,884 85,203
2022-06-30 $3,717,541 314,247
2021-06-30 $1,693,649 29,902